X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The grant will be used to advance AstriVax’ candidate CHB therapeutic vaccine in clinical development for the treatment of chronic Hepatitis B. It efficiently induces specific CD8+ T-cells.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Vaccine
Partner/Sponsor/Collaborator: Flanders Innovation & Entrepreneurship
Deal Size: $3.2 million Upfront Cash: Undisclosed
Deal Type: Funding December 12, 2023
Details:
The grant will accelerate the company’s vaccine platform. The company develops novel prophylactic and therapeutic vaccines that are easy to produce, have reduced cold chain requirements, and offer broad and long-lasting protection against various infectious diseases.
Lead Product(s): Undisclosed
Therapeutic Area: Technology Product Name: Undisclosed
Highest Development Status: Discovery PlatformProduct Type: Vaccine
Partner/Sponsor/Collaborator: VLAIO
Deal Size: $2.6 million Upfront Cash: Undisclosed
Deal Type: Funding May 30, 2023
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
